SCHEMBL1968973

SCHEMBL1968973

CCOC(=O)c1c(O)c2cccn2n(Cc2ccc(F)cc2F)c1=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.43
KDM4E B2RXH2 6/20 0.43
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
RECQL P46063 1/20 0.41
LMNA P02545 2/20 0.40
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALOX5 P09917 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
MAPK14 Q16539 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968107 0.89 KDM4E (0.50) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL1965910 0.85 ALDH1A1 (0.47) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL1966018 0.85 LMNA (0.49) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL1966882 0.83 ALDH1A1 (0.46) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL1965997 0.81 KDM4E (0.50) ALDH1A1KDM4ETDP1MEN1GAA
SCHEMBL1965742 0.80 KDM4E (0.47) ALDH1A1KDM4ETDP1MEN1GAA
SCHEMBL1967350 0.80 KDM4E (0.54) ALDH1A1KDM4EMEN1GAAHPGD
SCHEMBL1969663 0.79 EGLN1 (0.55)
SCHEMBL1967127 0.78 KDM4E (0.48) ALDH1A1KDM4ETDP1MEN1HPGD
SCHEMBL1966103 0.77 KMT2A (0.50) ALDH1A1KDM4EMEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 ALDH1A1 268/4885KDM4E 471/4885TDP1 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.